There is a high concordance (84.4%) of physician and patient global assessment of psoriatic arthritis disease activity from 538 paired assessments in the ARLAR multinational study, Maroof A et al, Abst #0506 #ACR23 @RheumNow https://t.co/NsT4MNWPVX https://t.co/TfuMj8qMXz

RA as a young woman used to mean kids were only a distant thought. Japanese RA pts n=280 asked whether RA onset meant wanting fewer children & why. Confidence improving across the board over time. We want to give our RA pts choices to live their life! #ACR23 ABST0473 @RheumNow https://t.co/OHZM2J5qxS

Tired of getting referrals for symptomatic patients with 1/80+ ANAs antibodies? This new risk model for systemic AID is very welcome! Variables: age, female, higher ANA titer, higher platelet count, disease-specific autoantibody & billing code count. #ACR23 @Rheumnow ABST0131 https://t.co/q8rYjjtZ89

Year in Review: Dr. P Seo Dr. Seo gave a moment of silence to Baricitinib use in SLE given studies showing it is not efficacious for SLE #ACR23 @RheumNow https://t.co/8GKUlfJdbe

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE COMPLETE ➡️ TNFi failures ➡️Phase III, 400 pts, bimekizumab, PBO ➡️ Wk 16: improvements in joint and skin #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Bimekizumab ➡️ Anti-IL17A, ANti-IL17F ab 🚩BE OPTIMAL ➡️ tx-naive ➡️Phase III, 852 pts, bimekizumab, PBO, ADA ➡️ Wk 16: same as ADA for joints, BETTER FOR SKIN #ACR23 @RheumNow

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Brepocitinib ➡️ Tyk-2 inhibitor: IL12/23 & type I IFN ➡️ Phase Ib, 218 pts, 8% TNFi failure ➡️ 71% on concurrent MTX ➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52 #ACR23 @RheumNow

These US Medicare data show us what we've all suspected: PMR patients stuck on steroid get the fractures, heart attacks, & infections that land them in hospital. And it costs $$$ Hopefully PMR steroid-sparing Rx can change this! @RADoctor @SattuiSEMD #ACR23 ABST0718 @RheumNow https://t.co/XAWmf2qZAU

Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️ABBV-3373 ➡️ Adalimumab (ADA) + GC receptor modulator vs ADA ➡️ Phase II, 48 pts, previously failed MTX ➡️ Wk 12: better DAS28-CRP, ACR20/70 🚩71% of responders stayed in remission after switch to PBO #ACR23 @RheumNow

Difficult to treat RA is not an homogeneous group! Trajectory analysis 60months shows 4 different clusters Cluster 2 = 1/3 of patients, do better but never reach LDA. The ones Fibromyalgia, OA and other conditions blurring assessment? #Abstract0382 #ACR23 @RheumNow https://t.co/dxxS7vCcMt

Dr. Arbeeva explains how a "modern diet" can lead to MetS, intestinal dysbiosis & obesity - risk factors assoc w/ development of #osteoarthritis Modern diet: ⬆️calorie processed food ⬇️proportion of fruits & veggies ⬆️ratio of omega-6 FA:omega-3FA #ACR23 @rheumnow @rheumarhyme https://t.co/biVSE103S0

Year in Review: Dr. P Seo ⭐️Low dose colchicine assoc w/ ⬇️ incidence of hip/knee replacement ➡️ 5522 pts w/ stable CAD: colchicine 0.5 mg vs PBO for median of 28.6 months ➡️ Hip/knee: 2.5% vs 3.5% ➡️HR 0.69 Similar finding in 2020 CANTOS trial using Ilaris #ACR23 @RheumNow https://t.co/PD26zoolDB

Calling #rheumtwitter program directors! #ACR23 Plenary 0726 details considerations for developing MSUS curriculum from Canadian experts. Details below. https://t.co/VmbxkYwlcr @rheumnow https://t.co/5nrpDk0Dsc

Thinking beyond immunosuppression for SLE Nephritis management: SGLT-2i GLP-1RA ERAs @RheumNow #ACR23 https://t.co/RdmKnm08YY

Love teaching about the PsA-AxSpa-IBD venn diagram of disease manifestations Interesting idea, using fecal calprotectin to trigger colonoscopy in pts w/PsA/axSpA ~40% w/pathologic finding, 4.4% dx w/IBD Jives w/my clinical experience @RheumNow #ACR23 Abstr0495 #ACRBest https://t.co/rIQpJnup9v